MELBOURNE, Australia--(BUSINESS WIRE)--The Melbourne-based biotechnology company, Phosphagenics Limited (ASX:POH, OTCQX:PPGNY) announced today the signing of a global agreement to develop their patented transdermal (TPM) insulin delivery system for the treatment of diabetes in companion animals.
